Rubius Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | $1.58 | $1.58 | $1.58 |
| Q2 2024 | 0 | $1.34 | $1.34 | $1.34 |
| Q3 2024 | 0 | $1.54 | $1.54 | $1.54 |
Rubius Therapeutics, Inc. Earnings Date And Information
Rubius Therapeutics, Inc. last posted its earnings results on Wednesday, November 9th, 2022. The company reported $-0.37 earnings per share for the quarter, topping analysts' consensus estimates of $-0.42 by $0.05. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Rubius Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.56 diluted earnings per share) and currently has a price-to-earnings ratio of -0.03. Rubius Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, February 25th, 2024 based on prior year's report dates.
Rubius Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/27/2023 | Q4 2022 | -$0.46 | $0 | $0 | ||
| 11/09/2022 | Q3 2022 | -$0.42 | -$1.03 | -0.61 | $0 | |
| 08/09/2022 | Q2 2022 | -$0.52 | -$0.50 | 0.02 | $0 | |
| 05/10/2022 | Q1 2022 | -$0.57 | -$0.60 | -0.03 | $0 | |
| 02/25/2022 | Q4 2021 | -$0.58 | -$0.61 | -0.03 | $0 | |
| 11/08/2021 | Q3 2021 | -$0.56 | -$0.55 | 0.01 | $0 | |
| 08/09/2021 | Q2 2021 | -$0.48 | -$0.56 | -0.08 | $0 | |
| 05/10/2021 | Q1 2021 | -$0.54 | -$0.51 | 0.03 | $0 | |
| 02/23/2021 | Q4 2020 | -$0.53 | -$0.50 | 0.03 | $0 | |
| 11/09/2020 | Q3 2020 | -$0.50 | -$0.51 | -0.01 | $0 | |
| 08/10/2020 | Q2 2020 | -$0.54 | -$0.47 | 0.07 | $0 | |
| 05/11/2020 | Q1 2020 | -$0.57 | -$0.60 | -0.03 | $0 | |
| 03/12/2020 | Q4 2019 | -$0.60 | -$0.56 | 0.04 | $0 | |
| 11/14/2019 | Q3 2019 | -$0.53 | -$0.59 | -0.06 | $0 | |
| 08/13/2019 | Q2 2019 | -$0.46 | -$0.50 | -0.04 | $0 | |
| 05/15/2019 | Q1 2019 | -$0.38 | -$0.42 | -0.04 | $0 | |
| 03/28/2019 | Q4 2018 | -$0.42 | -$0.35 | 0.07 | $0 | |
| 11/13/2018 | Q3 2018 | -$0.36 | -$0.42 | -0.06 | $0 | |
| 08/31/2018 | Q2 2018 | -$0.38 | $0 | |||
| 03/30/2018 | Q1 2018 | -$1.83 | $0 |
Rubius Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Rubius Therapeutics, Inc.'s earnings date?
Rubius Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, February 25th, 2024 based off last year's report dates.
-
Did Rubius Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Rubius Therapeutics, Inc. (:RUBY) reported $-0.37 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.42 by $0.05.
-
How can I listen to Rubius Therapeutics, Inc.'s earnings conference call?
The conference call for Rubius Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Rubius Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Rubius Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Rubius Therapeutics, Inc. generate each year?
Rubius Therapeutics, Inc. (:RUBY) has a recorded net income of $0. Rubius Therapeutics, Inc. has generated $-2.56 earnings per share over the last four quarters.
-
What is Rubius Therapeutics, Inc.'s price-to-earnings ratio?
Rubius Therapeutics, Inc. (:RUBY) has a price-to-earnings ratio of -0.03 and price/earnings-to-growth ratio is -0.
